サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439923

乳がん診断 - 世界市場の考察、競合情勢、市場予測（2030年）

Breast Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
乳がん診断 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の乳がん診断の市場規模は、2023年に42億米ドル、2030年までに61億6,000万米ドルに達し、2024年～2030年の予測期間にCAGRで6.67％の成長が見込まれます。市場は、乳がんの有病率の増加、高齢化と座りがちな生活習慣の増加、技術の進歩、検診率および診断率を高める政府の取り組みの増加などの要因によってプラス成長を示しており、これらが2024年～2030年の予測期間に市場の成長を促進します。

乳がん診断の市場力学

乳がん診断市場の主な促進要因の1つは、世界の乳がん罹患率の増加です。世界保健機関（WHO）の2022年のデータによると、2020年に世界で230万人の女性が乳がんと診断されました。さらに、同資料によると、2020年末までに、過去5年間に乳がんと診断された生存女性は780万人であり、世界でもっとも有病率の高いがんとなっています。

したがって、世界中で乳がんの有病率が上昇すれば、乳がん診断に対する需要が増加し、予測期間（2024年～2030年）における乳がん診断市場の成長を促進します。

さらに、乳がん診断市場の成長をもたらしているもう1つの主な要因が、特定国政府による、早期の検診と診断に関する認識を高める取り組みの増加です。例えば、WHOは2022年3月、世界の乳がん死亡率を年率2.5%削減するGlobal Breast Cancer Initiative（GBCI）を立ち上げ、70歳未満の女性では2030年までに25%、2040年までに40%の乳がんによる死亡を防ぐとしています。乳がんの徴候、症状、早期発見、治療などに関する情報を提供することは、乳がんの診断と治療について一般の人々に認識させることになり、乳がん診断市場の需要を増加させます。

しかし、乳がんの診断の高いコストや、偽陽性などの診断の限界、マンモグラムによる過剰診断が不必要な治療につながることが、乳がん診断市場の成長を鈍化させる可能性があります。

COVID-19パンデミックは、COVID-19に罹患した患者に比べ、がんやその他の疾患に罹患した患者の入院が後回しにされたことから、乳がん診断市場に若干マイナスの影響を与えました。厳しいロックダウン規制、スタッフの不足、マスクやPPEキットの不足とともに、病院における乳がん患者の入院に大きな影響を与えました。しかし、大衆がワクチン接種を受け、医療部門の活動が再開されたことで、乳がん診断市場は勢いを取り戻し、予測期間にさらなる成長が見込まれます。

乳がん診断市場のセグメント分析

乳がん診断市場のタイプセグメントでは、マンモグラフィ、超音波、乳房MRI, CTスキャンなどの画像診断技術による診断が、予測期間に大きなシェアを占める見込みです。これは、マンモグラフィによる乳房組織の低線量X線画像や、乳がんの早期かつタイムリーな発見、化学療法を受けるリスクの低減など、画像診断技術に関連するさまざまな利点によるものです。例えば、2022年7月のNational Cancer Instituteによると、U.S. Preventive Task Forceは、50～74歳の女性の76.4％が過去2年以内にマンモグラフィを受けることを推奨しています。2030年までには、50～74歳の女性の77.1％が乳がん検診を受けていることになります。

さらに2022年1月、Duke Universityの研究者たちは、マンモグラフィ検査でがんの可能性がある病変を分析し、患者が侵襲的な生検を受けるべきかどうかを判断するAIプラットフォームを作成しました。このAIは、マンモグラフィ画像の読影方法のトレーニングに使用できる疑わしい病変を検出するのに役立ち、医師が医療判断を下すのに役立ちます。さらに、このAI技術は賢明な決断を下すために使用される可能性があり、画像診断の需要を増加させるため、2024年～2030年の予測期間に乳がん診断機器市場の成長を促進します。

当レポートでは、世界の乳がん診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 乳がん診断市場レポートのイントロダクション

第2章 乳がん診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 乳がん診断市場の主な要因の分析

  • 乳がん診断市場の促進要因
    • 乳がんの罹患率の増加
    • 老年人口の増加
    • 技術の進歩
    • 検診率と診断率を高める政府の取り組み。
  • 乳がん診断市場の抑制要因と課題
    • 乳がんの診断の高いコスト
    • マンモグラフィにおける診断の限界（偽陽性や過剰診断など）
  • 乳がん診断市場の機会
    • 乳がん診断中に良好な結果をもたらす免疫療法

第5章 乳がん診断市場のポーターのファイブフォース分析

第6章 乳がん診断に対するCOVID-19の影響分析

第7章 乳がん診断市場のレイアウト

  • 製品タイプ
    • 器具
    • 試薬、消耗品
  • タイプ別
    • イメージング
    • 臨床検査
  • エンドユーザータイプ別
    • 病院
    • 診断検査室
    • がん研究センター
    • その他
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 乳がん診断市場の企業と製品のプロファイル

  • Niramai Health Analytix
  • UE LifeSciences Inc
  • Xuzhou AKX Electronic Science and Technology Co Ltd
  • Koning Health
  • Kheiron Medical Technologies Limited
  • Technomax Corporation
  • General Electric Company
  • Hologic Inc.
  • Koninklijke Philips N.V
  • Fujifilm Corporation
  • Canon Medical Systems Argentina S.A
  • Hitachi Ltd
  • Carestream Health
  • Planmed Oy
  • SonoCine
  • Siemens Healthcare GmbH
  • Seno Medical
  • Stryker
  • Izotropic Corporation
  • CMR Naviscan

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Breast Cancer Diagnostics Market in Global (2021-2030)
  • Table 4: Breast Cancer Diagnostics Market in Global by Product Type (2021-2030)
  • Table 5: Breast Cancer Diagnostics Market in Global by Type (2021-2030)
  • Table 6: Breast Cancer Diagnostics Market in Global by End-user (2021-2030)
  • Table 7: Breast Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Table 8: Breast Cancer Diagnostics Market in North America (2021-2030)
  • Table 9: Breast Cancer Diagnostics Market in North America by Country (2021-2030)
  • Table 10: Breast Cancer Diagnostics Market in the US (2021-2030)
  • Table 11: Breast Cancer Diagnostics Market in Canada (2021-2030)
  • Table 12: Breast Cancer Diagnostics Market in Mexico (2021-2030)
  • Table 13: Breast Cancer Diagnostics Market in Europe (2021-2030)
  • Table 14: Breast Cancer Diagnostics Market in Europe by Country (2021-2030)
  • Table 15: Breast Cancer Diagnostics Market in France (2021-2030)
  • Table 16: Breast Cancer Diagnostics Market in Germany (2021-2030)
  • Table 17: Breast Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Table 18: Breast Cancer Diagnostics Market in Italy (2021-2030)
  • Table 19: Breast Cancer Diagnostics Market in Spain (2021-2030)
  • Table 20: Breast Cancer Diagnostics Market in the Rest of Europe (2021-2030)
  • Table 21: Breast Cancer Diagnostics Market in APAC (2021-2030)
  • Table 22: Breast Cancer Diagnostics Market in APAC by Country (2021-2030)
  • Table 23: Breast Cancer Diagnostics Market in China (2021-2030)
  • Table 24: Breast Cancer Diagnostics Market in Japan (2021-2030)
  • Table 25: Breast Cancer Diagnostics Market in India (2021-2030)
  • Table 26: Breast Cancer Diagnostics Market in Australia (2021-2030)
  • Table 27: Breast Cancer Diagnostics Market in South Korea (2021-2030)
  • Table 28: Breast Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Table 29: Breast Cancer Diagnostics Market in the Rest of the World (2021-2030)
  • Table 30: Breast Cancer Diagnostics Market in RoW by Region (2021-2030)
  • Table 31: Breast Cancer Diagnostics Market in the Middle East (2021-2030)
  • Table 32: Breast Cancer Diagnostics Market in Africa (2021-2030)
  • Table 33: Breast Cancer Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Breast Cancer Diagnostics Market in Global (2021-2030)
  • Figure 4: Breast Cancer Diagnostics Market in Global by Product Type (2021-2030)
  • Figure 5: Breast Cancer Diagnostics Market in Global by Type (2021-2030)
  • Figure 6: Breast Cancer Diagnostics Market in Global by End-user (2021-2030)
  • Figure 7: Breast Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Figure 8: Breast Cancer Diagnostics Market in North America (2021-2030)
  • Figure 9: Breast Cancer Diagnostics Market in North America by Country (2021-2030)
  • Figure 10: Breast Cancer Diagnostics Market in the US (2021-2030)
  • Figure 11: Breast Cancer Diagnostics Market in Canada (2021-2030)
  • Figure 12: Breast Cancer Diagnostics Market in Mexico (2021-2030)
  • Figure 13: Breast Cancer Diagnostics Market in Europe (2021-2030)
  • Figure 14: Breast Cancer Diagnostics Market in Europe by Country (2021-2030)
  • Figure 15: Breast Cancer Diagnostics Market in France (2021-2030)
  • Figure 16: Breast Cancer Diagnostics Market in Germany (2021-2030)
  • Figure 17: Breast Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 18: Breast Cancer Diagnostics Market in Italy (2021-2030)
  • Figure 19: Breast Cancer Diagnostics Market in Spain (2021-2030)
  • Figure 20: Breast Cancer Diagnostics Market in the Rest of Europe (2021-2030)
  • Figure 21: Breast Cancer Diagnostics Market in APAC (2021-2030)
  • Figure 22: Breast Cancer Diagnostics Market in APAC by Country (2021-2030)
  • Figure 23: Breast Cancer Diagnostics Market in China (2021-2030)
  • Figure 24: Breast Cancer Diagnostics Market in Japan (2021-2030)
  • Figure 25: Breast Cancer Diagnostics Market in India (2021-2030)
  • Figure 26: Breast Cancer Diagnostics Market in Australia (2021-2030)
  • Figure 27: Breast Cancer Diagnostics Market in South Korea (2021-2030)
  • Figure 28: Breast Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 29: Breast Cancer Diagnostics Market in the Rest of the World (2021-2030)
  • Figure 30: Breast Cancer Diagnostics Market in RoW by Region (2021-2030)
  • Figure 31: Breast Cancer Diagnostics Market in the Middle East (2021-2030)
  • Figure 32: Breast Cancer Diagnostics Market in Africa (2021-2030)
  • Figure 33: Breast Cancer Diagnostics Market in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Marker Opportunities
  • Figure 37: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0604

Breast Cancer Diagnostics Market By Product Type (Instrument, Reagent, And Consumables), By Type (Imaging, Lab Test), By End-User Type (Hospitals, Diagnostic Laboratories, Cancer Research Centers, Others), and by geography is expected to grow at a steady CAGR during the given forecast period owing to increase in the prevalence of breast cancer globally, growing geriatric population, the rising number of government initiatives to increase screening and diagnosis, and the increasing number of technological advancements.

The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030. The breast cancer diagnostics market is witnessing positive growth owing to factors such as the increasing prevalence of breast cancer, increasing age and sedentary lifestyle, technological advancements, rising number of government initiatives to increase the rate of screening and diagnosis, thereby driving the growth of the breast cancer diagnostics market during the forecast period from 2024-2030.

Breast Cancer Diagnostics Market Dynamics:

One of the main drivers of the breast cancer diagnostics market is the increasing prevalence of breast cancer globally. As per the World Health Organization (WHO) 2022 data, in 2020 breast cancer was diagnosed in 2.3 million women globally. Further, as per the same source by the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the last 5 years, making it the world's most prevalent cancer.

Therefore, an increase in the prevalence of breast cancer around the world would lead to an increase in the demand for breast cancer diagnostics, thereby propelling the growth of the breast cancer diagnostics market during the forecast period (2024-2030).

Moreover, another key factor that is responsible for the growth of the breast cancer diagnostics market is the rising number of initiatives taken by specific national governments to increase awareness about early screening and diagnosis. For instance, in March 2022, WHO launched a Global Breast Cancer Initiative (GBCI) to reduce global breast cancer mortality by 2.5% per year, which would prevent 25% of breast cancer deaths by 2030 and 40% by 2040 among women under 70 years of age. Providing information about signs, symptoms, early detection, treatment, etc. of breast cancer would aware public of breast cancer diagnosis and treatment which would increase the demand for the breast cancer diagnostics market.

However, the high cost of diagnosis of breast cancer, limitations in diagnosis like false-positive results, and overdiagnosis with mammogram leads to unnecessary treatments which can slow down the breast cancer diagnostics market growth.

The COVID-19 pandemic has slightly impacted the market for breast cancer diagnostics market negatively as hospital admissions for patients suffering from cancers and other disorders were not a priority in comparison to the patients suffering from coronavirus. Along with strict lockdown regulations, a lack of staff, and a shortage of masks and PPE kits made a huge impact on breast cancer patient admissions in hospitals. However, with the masses being vaccinated and the resumption of activities in the healthcare sector, the breast cancer diagnostics market has picked momentum and is expected to further grow during the forecast period.

Breast Cancer Diagnostics Market Segment Analysis:

Breast cancer diagnostics market by product type (instrument, reagent, and consumables), type (imaging, lab test), end-user type (hospitals, diagnostic laboratories, cancer research centers, others), and by geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the breast cancer diagnostics market, diagnosis through imaging techniques such as mammography, ultrasound, breast MRI, and CT scan is expected to hold a significant share during the forecast period, owing to the various benefits associated with them such as low-dose x-ray image of breast tissue through a mammogram, early and timely detection of breast cancer, thereby also reducing the risks of undergoing chemotherapy. For example, according to the National Cancer Institute July 2022, U.S. preventive task force recommends that 76.4% of women aged 50-74 years had mammography within the past 2 years. By 2030, 77.1 % proportion of women aged 50-74 years would have received breast cancer screening.

In addition, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians to take health care decisions. Furthermore, this AI technology could be used for making wise decisions, increasing the demand for image diagnosis, thus driving the growth of the breast cancer diagnostics devices market during the forecast period from 2024-2030.

North America is expected to dominate the overall Breast Cancer Diagnostics Market:

Among all the regions, North America is expected to dominate the global breast cancer diagnostics market during the forecast period from 2024-2030. Factors such as aging, race, and ethnicity drive breast cancer which increase the demand for breast cancer diagnostics in the North America market.

According to the American Cancer Society (2023), in January 2022 in the US, variations in breast cancer could be seen due to differences in racial and ethnic groups. The age of diagnosis was slightly younger for black women (age 60), followed by white women (age 63). Black women also have a higher death rate in this as 1 in 5 black women have triple-negative breast cancer which was more than in any other racial/ethnic group.

Furthermore, aging is the biggest risk factor for breast cancer. As people grow older, the chances of developing cancer increase. According to the same source in February 2022, 1 out of 8 women younger than 45 developed invasive breast cancer, and 2 out of 3 invasive breast cancers were found in women 55 or older.

The Breast Cancer Organization (2023) also mentioned that as of January 2022, more than 3.8 million women had a history of breast cancer in the US. One in eight American women (13%) was expected to develop invasive breast cancer at some point in their lives on average. In men, 2,710 new cases of invasive breast cancer are expected to be diagnosed by 2022 end in the US.

Therefore, the rising prevalence of breast cancer, aging, race, and ethnicity would result in the rising demand for breast cancer diagnostics which in turn would provide a conducive growth environment for the North America breast cancer diagnostics market.

Breast Cancer Diagnostics Market Key Players:

Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.

Recent Developmental Activities in the Breast Cancer Diagnostics:

In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography device).

In Jan 2022, UE LifeSciences entered into a definitive distribution agreement with Siemens Healthineers, adding its flagship device iBreastExam to Siemens' 360-degree breast care product portfolio for the U.S. market.

In Nov 2022, Kheiron Medical Technologies Launched RSViP to Help U.S. Breast Screening Programs Tackle Backlogs Worsened by COVID-19.

In Jan 2022, Kheiron's AI Breast Screening Solution Mia Receives Regulatory Clearance in Australia and New Zealand.

Key Takeaways from the Breast Cancer Diagnostics Market Report Study

  • Market size analysis for current breast cancer diagnostics market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching breast cancer diagnostics.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global breast cancer diagnostics.
  • Various opportunities are available for other competitors in the breast cancer diagnostics market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current breast cancer diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for breast cancer diagnostics market growth in the coming future?

Target Audience who can be benefited from this Breast Cancer Diagnostics Market Report Study

  • Breast cancer diagnostics products providers
  • Research organizations and consulting companies
  • Breast cancer diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Breast cancer diagnostics
  • Various End-users who want to know more about the Breast cancer diagnostics Market and the latest technological developments in Breast cancer diagnostics.

Frequently Asked Questions for Breast Cancer Diagnostics:

1. What are breast cancer diagnostics?

Breast cancer diagnostics are used detect breast cancer in men and women experiencing its signs and symptoms. Early diagnosis could improve cancer treatment by providing care at the earliest stage possible.

2. What is the market for Global breast cancer diagnostics?

The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030.

3. What are the drivers for the Global breast cancer diagnostics Market?

The breast cancer diagnostics market is witnessing positive market growth owing to the factors such as, increasing prevalence of breast cancer, Increasing age and sedentary lifestyle, inherited breast cancer genes, race, ethnicity, technological advancements, and government initiatives to increase the rate of screening and diagnosis.

4. Who are the key players operating in the breast cancer diagnostics Market?

Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.

5. Which region has the highest share in the breast cancer diagnostics Market?

North America is expected to dominate the global breast cancer diagnostics market. Factors contributing to its growth are the increasing prevalence of breast cancer due to aging, race, ethnicity, and others, increasing the demand for breast cancer diagnostics, thus driving the breast cancer diagnostics market growth in North America region.

Table of Contents

1.Breast Cancer Diagnostics Market Report Introduction

2.Breast Cancer Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The US
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Breast Cancer Diagnostics Market Key Factors Analysis

  • 4.1. Breast Cancer Diagnostics Market Drivers
    • 4.1.1. Increasing Prevalence of Breast Cancer
    • 4.1.2. Rising Geriatric Population
    • 4.1.3. Technological Advancements
    • 4.1.4. Government Initiatives to Increase the Rate of Screening and Diagnosis.
  • 4.2. Breast Cancer Diagnostics Market Restraints And Challenges
    • 4.2.1. High Cost Of Diagnosis Of Breast Cancer
    • 4.2.2. Limitation In Diagnosis Like In Mammogram Like False-Positive Results And Overdiagnosis
  • 4.3. Breast Cancer Diagnostics Market Opportunities
    • 4.3.1. Immunotherapy yielding positive results during breast cancer diagnosis

5. Breast Cancer Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Breast Cancer Diagnostics

7. Breast Cancer Diagnostics Market Layout

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagent and Consumables
  • 7.2. By Type
    • 7.2.1. Imaging
    • 7.2.2. Lab test
  • 7.3. By End User Type
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Laboratories
    • 7.3.3. Cancer Research Centers
    • 7.3.4. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. North America Breast Cancer Diagnostics Market, by Country
      • 7.4.1.1.1. US Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.1.1.2. Canada Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.1.1.3. Mexico Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. Europe Breast Cancer Diagnostics Market, by Country
      • 7.4.2.1.1. France Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.2. Germany Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.3. United Kingdom Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.4. Italy Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.5. Spain Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.6. Rest of Europe Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. Asia-Pacific Breast Cancer Diagnostics Market, by Country
      • 7.4.3.1.1. China Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.2. Japan Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.3. India Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.4. Australia Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.5. South Korea Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.6. Rest of Asia Pacific Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. RoW Breast Cancer Diagnostics Market, by Region
      • 7.4.4.1.1. Middle East Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.4.1.2. Africa Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.4.1.3. South America Breast Cancer Diagnostics Market in USD million (2021-2030)

8. Breast Cancer Diagnostics Market Company and Product Profiles

  • 8.1. Niramai Health Analytix
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. UE LifeSciences Inc
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Xuzhou AKX Electronic Science and Technology Co Ltd
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Koning Health
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Kheiron Medical Technologies Limited
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Technomax Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. General Electric Company
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Hologic Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Koninklijke Philips N.V
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Fujifilm Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Canon Medical Systems Argentina S.A
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Hitachi Ltd
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Carestream Health
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Planmed Oy
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. SonoCine
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Siemens Healthcare GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Seno Medical
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Stryker
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Izotropic Corporation
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. CMR Naviscan
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us